Literature DB >> 33560041

Population Viral Load, Viremia, and Recent HIV-1 Infections: Findings From Population-Based HIV Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia.

Mansoor Farahani1, Elizabeth Radin1, Suzue Saito1, Karampreet K Sachathep1, Wolfgang Hladik2, Andrew C Voetsch2, Andrew F Auld3, Shirish Balachandra4, Beth A Tippett Barr5, Andrea Low1, Theodore F Smart1, Godfrey Musuka6, Sasi Jonnalagadda2, Avi J Hakim2, Nellie W Wadonda-Kabondo3, Andreas Jahn7, Owen Mugurungi8, Daniel B Williams2, Danielle T Barradas9, Danielle Payne3, Bharat Parekh2, Hetal Patel2, Lubbe Wiesner10, David Hoos1, Jessica E Justman1.   

Abstract

BACKGROUND: HIV population viral load (PVL) can reflect antiretroviral therapy program effectiveness and transmission potential in a community. Using nationally representative data from household surveys conducted in Zimbabwe, Malawi, and Zambia in 2015-16, we examined the association between various VL measures and the probability of at least one recent HIV-1 infection in the community.
METHODS: We used limiting-antigen avidity enzyme immunoassay, viral load suppression (VLS) (HIV RNA <1000 copies/mL), and antiretrovirals in the blood to identify recent HIV-1 cases.
RESULTS: Among 1510 enumeration areas (EAs) across the 3 surveys, 52,036 adults aged 15-59 years resided in 1363 (90.3%) EAs with at least one HIV-positive adult consenting to interview and blood draw and whose VL was tested. Mean HIV prevalence across these EAs was 13.1% [95% confidence intervals (CI) 12.7 to 13.5]. Mean VLS prevalence across these EAs was 58.7% (95% CI: 57.3 to 60.0). In multivariable analysis, PVL was associated with a recent HIV-1 case in that EA (adjusted odds ratio: 1.4, 95% CI: 1.2 to 1.6, P = 0.001). VLS prevalence was inversely correlated with recent infections (adjusted odds ratio: 0.3, 95% CI: 0.1 to 0.6, P = 0.004). The 90-90-90 indicators, namely, the prevalence of HIV diagnosis, antiretroviral therapy coverage, and VLS at the EA level, were inversely correlated with HIV recency at the EA level.
CONCLUSIONS: We found a strong association between PVL and VLS prevalence and recent HIV-1 infection at the EA level across 3 southern African countries with generalized HIV epidemics. These results suggest that population-based measures of VLS in communities may serve as a proxy for epidemic control.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33560041     DOI: 10.1097/QAI.0000000000002637

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  3 in total

1.  Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.

Authors:  Win Min Han; Matthew G Law; Matthias Egger; Kara Wools-Kaloustian; Richard Moore; Catherine McGowan; Nagalingesawaran Kumarasamy; Sophie Desmonde; Andrew Edmonds; Mary-Ann Davies; Constantin Yiannoutsos; Keri N Althoff; Claudia P Cortes; Thahira Jamal Mohamed; Antoine Jaquet; Kathryn Anastos; Jonathan Euvrard; Barbara Castelnuovo; Kate Salters; Lara Esteves Coelho; Didier K Ekouevi; Brian Eley; Lameck Diero; Elizabeth Zaniewski; Nathan Ford; Annette H Sohn; Azar Kariminia
Journal:  Lancet HIV       Date:  2021-12       Impact factor: 16.070

Review 2.  Risk scores for predicting HIV incidence among adult heterosexual populations in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Katherine M Jia; Hallie Eilerts; Olanrewaju Edun; Kevin Lam; Adam Howes; Matthew L Thomas; Jeffrey W Eaton
Journal:  J Int AIDS Soc       Date:  2022-01       Impact factor: 5.396

3.  Spatiotemporal Variation and Predictors of Unsuppressed Viral Load among HIV-Positive Men and Women in Rural and Peri-Urban KwaZulu-Natal, South Africa.

Authors:  Adenike O Soogun; Ayesha B M Kharsany; Temesgen Zewotir; Delia North; Ebenezer Ogunsakin; Perry Rakgoale
Journal:  Trop Med Infect Dis       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.